Marta V. Rivas

General San Martin, B, Argentina

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 57 publications

Serology as an early diagnostic tool in pediatric patients with Shiga toxin-producing Escherichia coli-associated hemolytic uremic syndrome: a post hoc analysis of a phase 2 clinical trial.

Serology as an early diagnostic tool in pediatric patients with Shiga toxin-producing Escherichia coli-associated hemolytic uremic syndrome: a post hoc analysis of a phase 2 clinical trial.

Journal: Journal of clinical microbiology

Published: February 27, 2026

INM004: Polyclonal Neutralizing Antibodies Against Shiga Toxin as a Treatment for Hemolytic Uremic Syndrome.

INM004: Polyclonal Neutralizing Antibodies Against Shiga Toxin as a Treatment for Hemolytic Uremic Syndrome.

Journal: Toxins

Published: March 29, 2025

A novel multiplex and glycoprotein-based immunochromatographic serologic IgM test for the rapid diagnosis of Escherichia coli O157 and O145 causing bloody diarrhea and hemolytic uremic syndrome.

A novel multiplex and glycoprotein-based immunochromatographic serologic IgM test for the rapid diagnosis of Escherichia coli O157 and O145 causing bloody diarrhea and hemolytic uremic syndrome.

Journal: Journal of clinical microbiology

Published: October 31, 2024

Development of a set of bacterial engineered glycoconjugates as novel serogroup-specific antigens for the serodiagnosis of Escherichia coli O26, O111, O103 and O45 infections associated to hemolytic uremic syndrome.

Development of a set of bacterial engineered glycoconjugates as novel serogroup-specific antigens for the serodiagnosis of Escherichia coli O26, O111, O103 and O45 infections associated to hemolytic uremic syndrome.

Journal: Microbial cell factories

Published: October 02, 2024

Open-label, controlled, phase 2 clinical trial assessing the safety, efficacy, and pharmacokinetics of INM004 in pediatric patients with Shiga toxin-producing Escherichia coli-associated hemolytic uremic syndrome.

Open-label, controlled, phase 2 clinical trial assessing the safety, efficacy, and pharmacokinetics of INM004 in pediatric patients with Shiga toxin-producing Escherichia coli-associated hemolytic uremic syndrome.

Journal: Pediatric nephrology (Berlin, Germany)

Published: July 16, 2024

Revisiting carboxylic group functionalization of silica sol-gel materials.

Revisiting carboxylic group functionalization of silica sol-gel materials.

Journal: Journal of materials chemistry. B

Published: February 08, 2023

Benzoxaborole-grafted high molecular weight chitosan from prawn: Synthesis, characterization, target recognition and antibacterial properties.

Benzoxaborole-grafted high molecular weight chitosan from prawn: Synthesis, characterization, target recognition and antibacterial properties.

Journal: Carbohydrate polymers

Published: December 16, 2022

Surveillance of Shiga toxin-producing Escherichia coli associated bloody diarrhea in Argentina.

Surveillance of Shiga toxin-producing Escherichia coli associated bloody diarrhea in Argentina.

Journal: Revista Argentina de microbiologia

Published: July 19, 2022

Safety and effectiveness of RBD-specific polyclonal equine F(ab´)2 fragments for the treatment of hospitalized patients with severe Covid-19 disease: A retrospective cohort study.

Safety and effectiveness of RBD-specific polyclonal equine F(ab´)2 fragments for the treatment of hospitalized patients with severe Covid-19 disease: A retrospective cohort study.

Journal: PloS one

Published: May 12, 2022

The Importance of Shiga Toxin-Producing Escherichia coli O145:NM[H28]/H28 Infections in Argentina, 1998-2020.

The Importance of Shiga Toxin-Producing Escherichia coli O145:NM[H28]/H28 Infections in Argentina, 1998-2020.

Journal: Microorganisms

Published: October 24, 2021

Hemolytic uremic syndrome associated with Shiga toxin-producing Escherichia coli infection in Argentina: update of serotypes and genotypes and their relationship with severity of the disease.

Hemolytic uremic syndrome associated with Shiga toxin-producing Escherichia coli infection in Argentina: update of serotypes and genotypes and their relationship with severity of the disease.

Journal: Pediatric nephrology (Berlin, Germany)

Published: November 08, 2020

Post-transplant cyclophosphamide demonstrates lower non-relapse mortality and better graft-versus-host disease/relapse-free survival compared with antithymocyte globulin in unrelated donor hematopoietic stem cell transplantation. A single-center experience.

Post-transplant cyclophosphamide demonstrates lower non-relapse mortality and better graft-versus-host disease/relapse-free survival compared with antithymocyte globulin in unrelated donor hematopoietic stem cell transplantation. A single-center experience.

Journal: Bone marrow transplantation

Published: July 14, 2020

Showing 1-12 of 57

Last Updated: 09/26/2026